- Record: found
- Abstract: not found
- Article: not found
Amethyst NSCLC trial: phase 2, parallel-arm study of receptor tyrosine kinase inhibitor MGCD265, in patients with advanced or metastatic non-small cell lung cancer with activating genetic alterations in mesenchymal-epithelial transition factor
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.